Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2025 · 10-Q
Revenue$328.00K$328.00Kno prior Q2 2024 on file Net Income-$1.60M-$1.60Mno prior Q2 2024 on file EPS Diluted-$0.02-$0.02no prior Q2 2024 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$1,407,000— Free Cash Flowderived-$1,415,000— Margins · derivedGross margin47.0%
Operating margin-580.8%
Net margin-487.5%
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end